Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$12 Mln
P/E Ratio
9.26
P/B Ratio
2.68
Industry P/E
--
Debt to Equity
--
ROE
-6.75 %
ROCE
-0.01 %
Div. Yield
0 %
Book Value
--
EPS
0.19
CFO
$-266.05 Mln
EBITDA
$-371.48 Mln
Net Profit
$-385.86 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
| -20.78 | -4.86 | -18.52 | -30.16 | -30.70 | -51.50 | -27.83 |
|
BSE Sensex*
| 2.52 | 3.37 | 6.44 | 8.80 | 12.18 | 20.37 | 11.43 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|
|
Minerva Neurosciences (NERV)
| -63.58 | 286.79 | -65.77 | -67.09 | 5.49 | 11.34 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.43 | 10,315.11 | 21.27 | 23.13 | |
| 298.55 | 8,705.27 | 22.77 | 66.44 | |
| 27.22 | 10,589.59 | -- | -28.77 | |
| 106.73 | 10,559.67 | 32.44 | 14.16 |
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the... treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts. Read more
Executive Chairman & CEO
Dr. Remy Luthringer Ph.D.
Executive Chairman & CEO
Dr. Remy Luthringer Ph.D.
Headquarters
Burlington, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Minerva Neurosciences Inc (NERV) stood at $ 37,144 Mln as on 31-Dec-24
The share price of Minerva Neurosciences Inc (NERV) is $1.76 (NASDAQ) as of 25-Apr-2025 16:00 EDT. Minerva Neurosciences Inc (NERV) has given a return of -30.7% in the last 3 years.
Minerva Neurosciences Inc (NERV) has a market capitalisation of $ 12 Mln as on 25-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Minerva Neurosciences Inc (NERV) is 9.26 times as on 25-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Minerva Neurosciences Inc (NERV) and enter the required number of quantities and click on buy to purchase the shares of Minerva Neurosciences Inc (NERV).
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone for the treatment of negative symptoms in patients with schizophrenia. The company also has exclusive rights to develop and commercialize MIN-301, a soluble recombinant form of the Neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders. Minerva Neurosciences, Inc. was incorporated in 2007 and is based in Burlington, Massachusetts.
The CEO & director of Dr. Remy Luthringer Ph.D.. is Minerva Neurosciences Inc (NERV), and CFO & Sr. VP is Dr. Remy Luthringer Ph.D..
There is no promoter pledging in Minerva Neurosciences Inc (NERV).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,014
|
|
|
1,003
|
|
|
956
|
|
|
867
|
| Minerva Neurosciences Inc (NERV) | Ratios |
|---|---|
|
Return on equity(%)
|
-0.01
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Minerva Neurosciences Inc (NERV) was $0 Mln.
$0.01
(
